Item 1.01 Entry into a Material Definitive Agreement.
Takeda License Agreement
On
September 18, 2018, Molecular Templates, Inc. (the Company) entered into a development collaboration and exclusive license agreement (the License Agreement) with Millennium Pharmaceuticals, Inc., a wholly-owned
subsidiary of Takeda Pharmaceutical Company Limited (Takeda), for the development and commercialization of products incorporating or comprised of one or more CD38
SLT-A
fusion proteins
(Licensed Products) for the treatment of patients with diseases such as multiple myeloma.
Pursuant to the License Agreement,
the parties will initially
co-develop
one or more of the Licensed Products up to and including Phase Ia clinical trials, with the Company having an option to continue to
co-develop
the Licensed Products following Phase Ia clinical trials. The Company may exercise its
co-development
option within a specified time period following
completion of the Phase Ia clinical trials with no additional fee by providing written notice of exercise to Takeda, provided the Company has paid all
co-development
costs due pursuant to the License Agreement
as of the date of such exercise. Pursuant to the terms of the License Agreement, Takeda will be responsible for all regulatory activities and commercialization of the Licensed Products. The Company has granted Takeda specified intellectual property
licenses to enable Takeda to perform its obligations and exercise its rights under the License Agreement, including exclusive license grants to enable Takeda to conduct development, manufacturing, and commercialization activities pursuant to the
terms of the License Agreement.
Pursuant to the License Agreement, the Company will receive an upfront payment of $30 million and,
if the Company exercises its
co-development
option and funds its share of development costs, it may receive up to an additional $307.5 million in milestone payments upon the achievement of certain
development and regulatory milestone events and up to an additional $325 million in milestone payments upon the achievement of certain sales milestone events. If the Company does not exercise its
co-development
option, it may receive up to an additional $162.5 million in milestone payments upon the achievement of certain development and regulatory milestone events and up to an additional
$175 million in milestone payments upon the achievement of certain sales milestone events. The Company will also be entitled to receive tiered royalties, subject to certain reductions, as percentages of annual aggregate net sales, if any, of
Licensed Products. The royalty percentages would range from low double-digits to low twenties if the Company exercises its option to
co-develop,
and from high-single digits to low teens if the Company
does not exercise its option to
co-develop.
The parties will share in
co-development
costs in accordance with the terms of the License Agreement, and Takeda will be responsible for all costs incurred commercializing the Licensed Products.
Unless earlier terminated, the License Agreement will expire upon the expiration of the
last-to-expire
co-development
royalty term (or royalty term, if applicable) for a Licensed Product. Takeda has the right to terminate the License Agreement at any time
upon no less than ninety days prior written notice to the Company. Either party may, subject to specified cure periods, terminate the License Agreement in the event of the other partys uncured material breach, and either party may
terminate the License Agreement under specified circumstances relating to the other partys insolvency.
The License Agreement
contemplates that the Company will enter into certain ancillary arrangements with Takeda, including a clinical supply agreement and a quality agreement.
CPRIT Grant Contract
On
September 18, 2018, the Company entered into a Cancer Research Grant Contract (the Agreement) with the Cancer Prevention and Research Institute of Texas (CPRIT), in connection with a grant of approximately
$15.2 million awarded by CPRIT to the Company in November 2016 to fund research of a cancer therapy involving a CD38 targeting ETB
(MT-4019)
(the Award). Pursuant to the Agreement, the Company
may also use such funds to develop a replacement CD38 targeting ETB, with or without a partner. The Award is contingent upon funds being available during the term of the Agreement and subject to CPRITs ability to perform its obligations under
the Agreement as well as the Companys progress towards achievement of specified milestones, among other contractual requirements.